The CSP in ANY country is a de Facto EUA/Approval that gets the Molecule into the bodies of those in need. As results emerge the Other certifications will be an afterthought...and will have more effect on the share price than anything else...the point is this...the drug works..it's BEING USED on those in critical care...whether the FDAS' respond now or later...with a rubber stamp is a moot point...The News is always talking about getting it INTO the arms...it's happening...that's all we need for patient benefit and our benefit...